Date: March 25, 2013 By:
“Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade vaccine-induced immune responses.
Researchers from the Ragon Institute of Mass General, MIT, and Harvard University have now developed a new approach to vaccine design that may allow them to cut off those evolutionary escape routes. The researchers have developed and experimentally validated a computational method that can analyze viral protein sequences to determine how well different viral strains can reproduce in the body. That knowledge gives researchers an unprecedented guide for identifying viral vulnerabilities that could be exploited to design successful vaccine targets.
The team, led by Arup K. Chakraborty, the Robert T. Haslam Professor of Chemical Engineering, Chemistry, Physics and Biological Engineering at MIT, has designed protein fragments (peptides) that would target these weaknesses. Ragon Institute researchers are now developing ways to deliver the peptides so they can be tested in animals. ”
Read more at MIT News
Image: This scanning electron micrograph shows HIV particles infecting a human T cell. (Source: National Institutes of Health)
Researchers at the University of Amsterdam, in collaboration with the Batista Lab at the Ragon Institute, have developed a potential new approach for an HIV vaccine.
Researchers at the Ndhlovu Lab, part of the Ragon Institute and the Africa Health Research Institute (AHRI), have completed a significant study on the safety and practicality of lymph node excisions for HIV cure research in South Africa.
We spoke to Kim to learn more about her background, her research journey, and her experiences at the Ragon Institute over the past few months.